RT Journal Article
SR Electronic
T1 Short-term Neuropsychiatric Outcomes and Quality of Life in COVID-19 Survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.23.20190090
DO 10.1101/2020.09.23.20190090
A1 Méndez, Raúl
A1 Balanzá-Martínez, Vicent
A1 Luperdi, Sussy C.
A1 Estrada, Itziar
A1 Latorre, Ana
A1 González-Jiménez, Paula
A1 Feced, Laura
A1 Bouzas, Leyre
A1 Yépez, Katheryn
A1 Ferrando, Ana
A1 Hervás, David
A1 Zaldívar, Enrique
A1 Reyes, Soledad
A1 Berk, Michael
A1 Menéndez, Rosario
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.23.20190090.abstract
AB Background The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms, and QoL in COVID-19 survivors shortly after hospital discharge.Methods This was a cross-sectional analysis of a prospective study of hospitalized COVID-19 survivors followed-up for 2 months after discharge. A battery of standardized instruments evaluating neurocognitive function, psychiatric morbidity, and QoL (mental and physical components) was administered by telephone.Findings Of the 229 screened patients, 179 were included in the final analysis. Among survivors, the prevalence of moderately impaired immediate verbal memory and learning was 38%, delayed verbal memory (11.8%), verbal fluency (34.6%), and working memory (executive function) (6.1%), respectively. Moreover, 58.7% of patients had neurocognitive impairment in at least one function. Rates of positive screening for anxiety were 29.6%, depression (26.8%), and post-traumatic stress disorder (25.1%) respectively. In addition, 39.1% of the patients had psychiatric morbidity. Low QoL for physical and mental components was detected in 44.1% and 39.1% of patients, respectively. Delirium and stress-related symptoms increased approximately 4-fold the odds of developing neurocognitive impairment. Female gender and neurocognitive impairment diagnosis were related with an increase of 2.5 and 4.56- fold odds respectively of psychiatric morbidity.Interpretation Hospitalized COVID-19 survivors showed a high prevalence of neurocognitive impairment, psychiatric morbidity, and poor QoL in the short-term. It is uncertain if these impacts persist over the long-term.Competing Interest StatementDr. M. Berk reports grants from National Institute of Health, grants from Cooperative Research Centre, grants from Autism Foundation, grants from Cancer Council of Victoria, grants from Stanley Medical Research Foundation, grants from Medical Benefits Fund, grants from National Health and Medical Research Council, grants from Medical Research Futures Fund, grants from Beyond Blue, grants from Rotary Health, grants from A2 milk company, grants from Meat and Livestock Board, grants from Woolworths, grants from Avant and the Harry Windsor Foundation, non-financial support from Astra Zeneca, non-financial support from Lundbeck, non-financial support from Merck, other from Pfizer, other from Allergan, other from Astra Zeneca, other from Bioadvantex, other from Bionomics, other from Collaborative Medicinal Development, other from Lundbeck, other from Merck, other from Pfizer, other from Servier, outside the submitted work.Funding StatementThere was non-specific funding for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Biomedical Research Ethics Committee of La Fe University and Polytechnic Hospital reviewed and approved the study (2020-280-1)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are accessible upon reasonable request